The global ophthalmic drugs market is expected to grow at a CAGR of 4.5% from 2021 to 2030. The growth in the market is attributed to the increasing prevalence of eye diseases, rising awareness about eye care, and technological advancements in the field of ophthalmology.
Retinal disorders drugs segment accounted for the largest share in 2018 and is expected to continue its dominance throughout the forecast period. This segment includes drugs used for treating retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). Allergic, inflammatory and infectious drugs segment accounted for a significant share in 2018 due to increasing prevalence of allergic conjunctivitis, vernal keratoconjunctivitis, dry eye syndrome (DES), etc, which are treated with these types of medications. Glaucoma drugs segment accounted for a significant share in 2018 due to increased incidence rates among people aged 40 years or older which are treated with these types of medications. Dry eye syndrome drug segment accounted for a significant share in 2018 due to increased incidence rates among people aged 40 years or older which are treated with these types of medications.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of eye diseases.
- Increasing awareness about eye care.
- Growing geriatric population.
- Rising disposable income.
- Technological advancements in the field.
Industry Growth Insights published a new data on “Pharma Ophthalmic Market”. The research report is titled “Pharma Ophthalmic Market research by Types (Retinal Disorders Drugs, Allergic, Inflammatory and Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs), By Applications (Glaucoma, Dry Eye Syndrome, Retinal Diseases, Other Ophthalmic Indications), By Players/Companies Novartis, Allergan, Roche, Valeant, Regeneron, Santen, Bayer, Pfizer, Senju, Akorn”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharma Ophthalmic Market Research Report
By Type
Retinal Disorders Drugs, Allergic, Inflammatory and Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs
By Application
Glaucoma, Dry Eye Syndrome, Retinal Diseases, Other Ophthalmic Indications
By Companies
Novartis, Allergan, Roche, Valeant, Regeneron, Santen, Bayer, Pfizer, Senju, Akorn
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Pharma Ophthalmic Market Report Segments:
The global Pharma Ophthalmic market is segmented on the basis of:
Types
Retinal Disorders Drugs, Allergic, Inflammatory and Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Glaucoma, Dry Eye Syndrome, Retinal Diseases, Other Ophthalmic Indications
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Allergan
- Roche
- Valeant
- Regeneron
- Santen
- Bayer
- Pfizer
- Senju
- Akorn
Highlights of The Pharma Ophthalmic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Retinal Disorders Drugs
- Allergic, Inflammatory and Infective Drugs
- Glaucoma Drugs
- Dry Eye Drugs
- Other Ophthalmic Drugs
- By Application:
- Glaucoma
- Dry Eye Syndrome
- Retinal Diseases
- Other Ophthalmic Indications
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharma Ophthalmic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharma Ophthalmic is a global pharmaceutical company focused on the development and commercialization of innovative ophthalmic products. The company's product portfolio includes dry eye therapies, such as artificial tears and lubricants, as well as topical treatments for various eye diseases. Pharma Ophthalmic also manufactures and sells optical devices, including contact lenses and spectacle frames.
Some of the major companies in the pharma ophthalmic market are Novartis, Allergan, Roche, Valeant, Regeneron, Santen, Bayer, Pfizer, Senju, Akorn.
The pharma ophthalmic market is expected to register a CAGR of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pharma Ophthalmic Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pharma Ophthalmic Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pharma Ophthalmic Market - Supply Chain
4.5. Global Pharma Ophthalmic Market Forecast
4.5.1. Pharma Ophthalmic Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pharma Ophthalmic Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pharma Ophthalmic Market Absolute $ Opportunity
5. Global Pharma Ophthalmic Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pharma Ophthalmic Market Size and Volume Forecast by Type
5.3.1. Retinal Disorders Drugs
5.3.2. Allergic, Inflammatory and Infective Drugs
5.3.3. Glaucoma Drugs
5.3.4. Dry Eye Drugs
5.3.5. Other Ophthalmic Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pharma Ophthalmic Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pharma Ophthalmic Market Size and Volume Forecast by Application
6.3.1. Glaucoma
6.3.2. Dry Eye Syndrome
6.3.3. Retinal Diseases
6.3.4. Other Ophthalmic Indications
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pharma Ophthalmic Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pharma Ophthalmic Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pharma Ophthalmic Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pharma Ophthalmic Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pharma Ophthalmic Demand Share Forecast, 2019-2026
9. North America Pharma Ophthalmic Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pharma Ophthalmic Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pharma Ophthalmic Market Size and Volume Forecast by Application
9.4.1. Glaucoma
9.4.2. Dry Eye Syndrome
9.4.3. Retinal Diseases
9.4.4. Other Ophthalmic Indications
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pharma Ophthalmic Market Size and Volume Forecast by Type
9.7.1. Retinal Disorders Drugs
9.7.2. Allergic, Inflammatory and Infective Drugs
9.7.3. Glaucoma Drugs
9.7.4. Dry Eye Drugs
9.7.5. Other Ophthalmic Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pharma Ophthalmic Demand Share Forecast, 2019-2026
10. Latin America Pharma Ophthalmic Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pharma Ophthalmic Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pharma Ophthalmic Market Size and Volume Forecast by Application
10.4.1. Glaucoma
10.4.2. Dry Eye Syndrome
10.4.3. Retinal Diseases
10.4.4. Other Ophthalmic Indications
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pharma Ophthalmic Market Size and Volume Forecast by Type
10.7.1. Retinal Disorders Drugs
10.7.2. Allergic, Inflammatory and Infective Drugs
10.7.3. Glaucoma Drugs
10.7.4. Dry Eye Drugs
10.7.5. Other Ophthalmic Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pharma Ophthalmic Demand Share Forecast, 2019-2026
11. Europe Pharma Ophthalmic Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pharma Ophthalmic Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pharma Ophthalmic Market Size and Volume Forecast by Application
11.4.1. Glaucoma
11.4.2. Dry Eye Syndrome
11.4.3. Retinal Diseases
11.4.4. Other Ophthalmic Indications
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pharma Ophthalmic Market Size and Volume Forecast by Type
11.7.1. Retinal Disorders Drugs
11.7.2. Allergic, Inflammatory and Infective Drugs
11.7.3. Glaucoma Drugs
11.7.4. Dry Eye Drugs
11.7.5. Other Ophthalmic Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pharma Ophthalmic Demand Share, 2019-2026
12. Asia Pacific Pharma Ophthalmic Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pharma Ophthalmic Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pharma Ophthalmic Market Size and Volume Forecast by Application
12.4.1. Glaucoma
12.4.2. Dry Eye Syndrome
12.4.3. Retinal Diseases
12.4.4. Other Ophthalmic Indications
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pharma Ophthalmic Market Size and Volume Forecast by Type
12.7.1. Retinal Disorders Drugs
12.7.2. Allergic, Inflammatory and Infective Drugs
12.7.3. Glaucoma Drugs
12.7.4. Dry Eye Drugs
12.7.5. Other Ophthalmic Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pharma Ophthalmic Demand Share, 2019-2026
13. Middle East & Africa Pharma Ophthalmic Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pharma Ophthalmic Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pharma Ophthalmic Market Size and Volume Forecast by Application
13.4.1. Glaucoma
13.4.2. Dry Eye Syndrome
13.4.3. Retinal Diseases
13.4.4. Other Ophthalmic Indications
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pharma Ophthalmic Market Size and Volume Forecast by Type
13.7.1. Retinal Disorders Drugs
13.7.2. Allergic, Inflammatory and Infective Drugs
13.7.3. Glaucoma Drugs
13.7.4. Dry Eye Drugs
13.7.5. Other Ophthalmic Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pharma Ophthalmic Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pharma Ophthalmic Market: Market Share Analysis
14.2. Pharma Ophthalmic Distributors and Customers
14.3. Pharma Ophthalmic Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Allergan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Valeant
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Regeneron
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Santen
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bayer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Senju
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Akorn
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
